title: Enhanced international prognostic index in Japanese patients with diffuse large B-cell lymphoma.
abstract: To evaluate the National Comprehensive Cancer Network (NCCN) International Prognostic Index (IPI), we analyzed 284 patients treated with the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in our institution in Japan. Their 5-year overall survival (OS) by risk level was 80.7%, 74.8%, 55.4% and 67.5% (P=0.005); and their 5-year progression-free survival (PFS) was 76.8%, 78.6%, 63.7% and 58.3% (P=0.0722). The NCCN-IPI is a simple scale that uses conventional clinical factors, but did not reflect survival in our cohort. The NCCN-IPI may require further evaluation for different regions and ethnicities before adopting it for routine clinical use.
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Japan.
authors.forename: Aya
authors.initials: A
authors.lastname: Nakaya
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Japan.
authors.forename: Shinya
authors.initials: S
authors.lastname: Fujita
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Satake
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Japan.
authors.forename: Takahisa
authors.initials: T
authors.lastname: Nakanishi
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Japan.
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Azuma
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Japan.
authors.forename: Yukie
authors.initials: Y
authors.lastname: Tsubokura
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Japan.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Hotta
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Japan.
authors.forename: Hideaki
authors.initials: H
authors.lastname: Yoshimura
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Japan.
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Ishii
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Japan.
authors.forename: Tomoki
authors.initials: T
authors.lastname: Ito
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Japan.
authors.forename: Shosaku
authors.initials: S
authors.lastname: Nomura
keywords: Albumin; DLBCL; NCCN-IPI; Rituximab